

ASCO 2026



| Date | Time | Presenting Author | Session Type | Presentation Title | Location | Poster Board Number | Abstract Number |
|--|----------------------|--|-------------------------------|---|----------|---------------------|-----------------|
| 5/29/26 | 1:24 PM-1:36 PM | Steven J. Chmura, MD, PhD | Education | Stereotactic Body Radiotherapy for Oligometastatic and Oligoprogressive Hormone Receptor-Positive Breast Cancer: When and Why? | Hall D1 | | |
| Saturday, May 30, 2026 | | | | | | | |
| 5/30/26 | 8:10 - 8:35 AM | Blase N. Polite, MD, FASCO | | Funding the Future of Academic Oncology: Challenges, Opportunities, and Successful Tactics | S501abc | | |
| 5/30/26 | 8:12 - 8:24 | Peter H. O'Donnell, MD | Clinical Science Symposium | Health-related quality of life (HRQL) with neoadjuvant and adjuvant (neoadj-ad) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible: Phase 3 KEYNOTE-905 study. | Hall D2 | | |
| 5/30/26 | 8:42 - 8:48 AM | Gini F. Fleming, MD, FASCO | Rapid Oral Abstract Session | Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein-targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC). | E450a | | |
| 5/30/26 | 5:15 - 5:30 PM | Rita Nanda, MD, FASCO | Education | Advances in Systemic Treatment of Metastatic Triple-Negative Breast Cancer | Hall B1 | | |
| Symptom Science and Palliative Care | | | | | | | |
| 5/30/26 | 1:30 - 4:30 PM CDT | Jincong Q. Freeman, MPH, MS | Poster | Hearing/vestibular dysfunction and longitudinal changes in psychosocial well-being among breast cancer survivors. | Hall A | Poster Bd 67 | 12084 |
| Head and Neck Cancer | | | | | | | |
| 5/30/26 | 1:30 - 4:30 PM CDT | Ari Joseph Rosenberg, MD | Poster | Real-world treatment patterns and overall survival in recurrent/metastatic head and neck squamous cell carcinoma following treatment with immune checkpoint inhibitor and platinum-based chemotherapy. | Hall A | Poster Bd 495 | 6038 |
| 5/30/26 | 1:30 - 4:30 PM CDT | Izumchenko, Evgeny, PhD | Poster | Intrapatent comparative analysis of tumor-informed ctDNA and ctHPV-DNA in patients with HPV-driven OPSCC. | Hall A | Poster Bd 532 | 6075 |
| 5/30/26 | 1:30 - 4:30 PM CDT | Ari Joseph Rosenberg, MD | Poster | Neoadjuvant HPV16-specific viral immunotherapy (HB200) plus chemotherapy with response-adapted de-escalation in HPV16+ oropharyngeal squamous cell carcinoma: TARGET-HPV trial. | Hall A | Poster Bd 554 | 6097 |
| 5/30/26 | 1:30 - 4:30 PM CDT | Faith Abodunrin, MD | Poster | Anti-PD-1 immunotherapy with chemotherapy for poorly chemo-responsive thyroid and salivary gland tumors: The PRIME study. | Hall A | Poster Bd 581 | 6124 |
| Medical Student & Resident Research Forum | | | | | | | |
| 5/30/26 | 3:30 PM - 5:00 PM | Harveen Kaur MD | Poster | Characterization of CNS Radiation Exposure and CRS/ICANS Events in Patients Treated with Tarlatamab for Patients with Small Cell Lung Cancer | Hall C | | |
| Sunday, May 31, 2026 | | | | | | | |
| 5/31/26 | 10:30 - 10:45 AM CDT | Heather Leeper, MD, MSc | Education | Managing Dementia-Like Symptoms in Patients With Brain Tumors and Having Difficult Conversations | E350 | | |
| 5/31/26 | 10:57 - 11:03 AM | Jennifer H. Coopender, MD | Rapid Oral Abstract Session | Final analysis of daratumumab, carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. | E450a | | |
| 5/31/26 | 12:00 - 12:15 PM | Michael Russell Bishop, MD, FACP, FASCO | Education | Long-Term Toxicities: Late Immune Events, Metabolic Syndrome, and Secondary Malignancies | | | |
| Genitourinary Cancer—Kidney and Bladder | | | | | | | |
| 5/31/26 | 9:00 - 12:00 PM | Betul Gok Yavuz, MD, PhD | Poster | Deciphering the genomic landscape of renal cell carcinoma brain metastases. | Hall A | Poster Bd 3 | 4524 |
| Genitourinary Cancer—Prostate, Testicular, and Penile | | | | | | | |
| 5/31/26 | 9:00 - 12:00 PM | Alexandra Larkin, MPH | Poster | Classification tree phenotypes for early treatment-limiting toxicity after androgen receptor pathway inhibitor initiation in metastatic hormone-sensitive prostate cancer from the IRONMAN registry. | Hall A | Poster Bd 190 | 5095 |
| 5/31/26 | 9:00 - 12:00 PM | Aishwarya Atmakuri, BS | Poster | Spatially organized immune niches in high-grade primary prostate cancer. | Hall A | Poster Bd 213 | 5118 |
| Monday, June 01, 2026 | | | | | | | |
| 6/1/26 | 8:00 - 8:12 AM | Olufunmilayo I. Otopade, MBBS, FACP, FASCO | Education | Deploying Cascade Testing | S403 | | |
| 6/1/26 | 12:00 - 12:15 PM CDT | Marina Chiara Garassino, MD | Education | Debate (Pro Status Quo/Current Standard of Care): Yes—Newcomers and New Strategies Are Welcome but We Need More Data Before Implementation in Routine Clinical Care | Hall D1 | | |
| 6/1/26 | 1:30 - 1:45 PM | Daniel Olson, MD | Education | When to Push, When to Pull Back: Tailoring Therapy in Metastatic Melanoma | E450b | | |
| 6/1/26 | 4:45 - 5:00 PM CDT | Fay J. Hlubocky, PhD, MA, FASCO | Education | Fueling the Fire: Understanding Burnout and Other Work Traumas | E350 | | |
| Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft | | | | | | | |
| 6/1/26 | 9:00 - 12:00 PM | Apoorva Ravichandran, MD | Poster | Response to HDAC/mitoxantrone/venetoclax (HMV) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). | Hall A | Poster Bd 320 | 6527 |
| 6/1/26 | 9:00 - 12:00 PM | Rafael Madero Marroquin, MD | Poster | Phase 1 study of venetoclax combined with a 10-day regimen of decitabine in subjects with high-risk acute myeloid leukemia. | Hall A | Poster Bd 340 | 6547 |
| Quality Care/Health Services Research | | | | | | | |
| 6/1/26 | 9:00 - 12:00 PM | Waqas Haque, MD, MPH, MPhil | Poster | Clinical-stage AI-enabled therapeutic assets: An industry-wide analysis of scale, clinical progression, and company characteristics. | Hall A | Poster Bd 55 | 11072 |
| 6/1/26 | 9:00 - 12:00 PM | Benjamin Avi Derman, MD | Poster | Impact of remote therapeutic monitoring on time to discontinuation and acute care events among patients treated with immune checkpoint inhibitors. | Hall A | Poster Bd 91 | 11108 |
| Prevention, Risk Reduction, and Genetics | | | | | | | |
| 6/1/26 | 1:30 - 4:30 PM CDT | Muhammad Rafiqul Islam, MD, MBBS, FACP, MSPH | Poster | Precision risk stratification for lung cancer in COPD: Evidence from the All of Us Program. | Hall A | Poster Bd 498 | 10537 |
| 6/1/26 | 1:30 - 4:30 PM CDT | Sutin Wu, MD, PhD | Poster | Embedding germline genetic testing into African oncology care: Early results from the Genetic Cancer Families (GenCAF) program. | Hall A | Poster Bd 533 | 10572 |
| 6/1/26 | 1:30 - 4:30 PM CDT | Devon Kathleen Dietrich, BA | Poster | Association of sociodemographic, environmental, and health factors with early-onset cancer in a diverse urban cohort. | Hall A | Poster Bd 553 | 10592 |
| 6/1/26 | 1:30 - 4:30 PM CDT | Wenji Guo, MD, D.Phil | Poster | Genome-wide association and Mendelian randomization analyses of body mass index and breast cancer risk in women of African ancestry. | Hall A | Poster Bd 559 | 10598 |
| Breast Cancer—Local/Regional/Adjuvant | | | | | | | |
| 6/1/26 | 1:30 - 4:30 PM CDT | Armaan Jamal, BS | Poster | Chemotherapy, endocrine therapy, and cognitive impairment in long-term breast cancer survivors. | Hall A | Poster Bd 8 | 523 |
| 6/1/26 | 1:30 - 4:30 PM CDT | Frederick Howard, MD | Poster | Estimating individual benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer using causal multimodal artificial intelligence. | Hall A | Poster Bd 36 | 551 |
| 6/1/26 | 1:30 - 4:30 PM CDT | Frederick Howard, MD | Poster | Predicting recurrence and survival in hormone receptor-positive (HR+)HER2-negative (HER2-) early breast cancer (EBC) with machine learning models: Optimization of model complexity. | Hall A | Poster Bd 47 | 562 |
| 6/1/26 | 1:30 - 4:30 PM CDT | Maeve Hennessy, MBCh | Poster | Pathologic complete response in rare histologic subtypes of early-stage triple-negative breast cancer in the era of immunotherapy. | Hall A | Poster Bd 78 | 593 |
| Breast Cancer—Metastatic | | | | | | | |
| 6/1/26 | 1:30 - 4:30 PM CDT | Jincong Q. Freeman, MPH, MS | Poster | Rare histologic subtypes of triple-negative breast cancer: The impact of immunotherapy on outcomes for metastatic disease. | Hall A | Poster Bd 234 | 1120 |
| Tuesday, June 02, 2026 | | | | | | | |
| 6/2/26 | 8:45 - 9:00 AM | Sonali M. Smith, MD, FASCO | Highlights of the Day Session | Highlights in Lymphoma | Hall D1 | | |